Clinical observation on the treatment of erythema telangiectasia rosacea with electro-hydrodynamic droplet injection of botulinum toxin A
Objective To explore the clinical efficacy and safety of electro-hydrodynamic droplet injection of botulinum toxin type A(BTX-A)for the treatment of erythematotelangiectatic rosacea(ETR).Methods Twenty-seven females with ETR were treated with electro-hydrody-namic droplet injection of BTX-A at the Department of Dermatology and Cosmetology,the Second People's Hospital of Bijie City.The cumulative dose of unilateral face was 20-30 U,and 40-60 U per patient.Clinical erythema score,dermatology life quality index(DLQI),symptom and sign score,and adverse reactions were assessed before and 8 weeks after the treatment.Results All 27 patients completed the study.Patients showed significant improvements in the clinical erythema score(from 2.67±0.83 to 1.30±0.60,t=10.54,P＜0.001),DLQI(from 14.96±5.50 to 6.52±2.79,t=9.38,P＜0.001)8 weeks after the treatment.Similarly,the facial skin burning score,dryness score,itching score,flushing score,and edema score were also significantly de-creased(all P＜0.01 vs.baseline).However,the score of facial capillary dilation did not change significantly(P=0.1).No significant adverse reactions,such as pain,local bruising,facial mus-cle paralysis,or unnatural expressions,were observed.Conclusions Electro-hydrodynamic droplet injection of BTX-A is safe and effective for improving the symptoms such as erythema,burning,dry-ness,itching,flushing and edema,and quality of life in ETR patients.
erythematotelangiectatic rosaceabotulinum toxin Amicrodroplets injectiondermatology life quality index
国家科技期刊平台
NSTL
万方数据
